Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.
Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.
3 Biotech Stocks With Decent Dividend for a Steady Return
by Indrajit Bandyopadhyay
Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.
GILD or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. VRTX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Walmart, NIKE, TJX, Gilead Sciences and Schlumberger
by Zacks Equity Research
Walmart, NIKE, TJX, Gilead Sciences and Schlumberger are included in this Analyst Blog.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
Q3 Earnings Scorecard and Analyst Reports for Walmart, Nike & TJX
by Sheraz Mian
Today's Research Daily features a real-time scorecard of the Q3 earnings season and new research reports on 16 stocks, including Walmart, Nike & TJX.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Gilead Sciences (GILD) reachead $79.20 at the closing of the latest trading day, reflecting a +2% change compared to its last close.
Nurix (NRIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why
by Zacks Equity Research
The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.10, marking a -1.12% move from the previous day.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $75.53, moving +0.94% from the previous trading session.
AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study
by Zacks Equity Research
AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.
Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
by Zacks Equity Research
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $75.62, moving -0.07% from the previous trading session.
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
by Zacks Equity Research
Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.
Gilead Sciences (GILD) Stock Moves -0.31%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.80, marking a -0.31% move from the previous day.